• Earlier this week, Charles River Laboratories International reported second-quarter 2026 results with revenue of US$1,004.08 million and a small net loss of US$1.48 million, while cutting its 2026 GAAP EPS guidance to US$3.05–US$3.35 per share due to divestiture-related losses.
• Despite the GAAP loss and lower EPS guidance, the company raised its full-year adjusted earnings outlook after non-GAAP results beat expectations, highlighting strong momentum and margin potential in its Discovery and Safety Assessment segment supported by portfolio changes and lower non-human primate sourcing costs.
• We’ll now examine how this stronger-than-expected DSA performance and raised adjusted EPS outlook affect Charles River’s previously framed investment narrative.

AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Charles River Laboratories International Investment Narrative Recap

To stay invested in Charles River, you need to believe its Discovery and Safety Assessment business can offset pressure on traditional animal-based research and pricing. The latest results support DSA as the key short term catalyst, with strong bookings and raised adjusted EPS guidance, while the biggest immediate risk remains execution around portfolio divestitures and managing GAAP losses. The updated guidance does not remove these risks, but it does suggest underlying demand is holding up.

The most relevant recent announcement is the August 2026 earnings release and guidance update, which paired a cut to 2026 GAAP EPS (US$3.05–US$3.35) with higher non GAAP EPS guidance. For investors focused on margin recovery and free cash flow, this split between GAAP and adjusted numbers goes to the heart of the catalyst: whether DSA driven mix and lower non human primate costs can translate into cleaner, more sustainable earnings over time.

Yet investors should still be aware that the shift toward non animal testing and potential demand erosion for Charles River’s core services...

Charles River Laboratories International's narrative projects $4.1 billion revenue and $461.2 million earnings by 2029. This requires flat yearly revenue growth and an earnings increase of about $645.9 million from -$184.7 million today.

Uncover how Charles River Laboratories International's forecasts yield a $230.93 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts are far more cautious, assuming roughly flat revenue near US$4.0 billion and 2029 EPS of about US$7.59, so you should recognize how differently others view the same DSA strength and GAAP weakness and consider how this quarter might shift those expectations.

Explore 4 other fair value estimates on Charles River Laboratories International - why the stock might be worth as much as 18% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.